GENEVA – Within months, insulin manufactured in Egypt will be available for distribution in sub-Saharan Africa, thanks to a collaboration between Eli Lilly and a local manufacturer that aims to produce one million doses of insulin by 2030.

Eli Lilly is providing Egypt’s EVA Pharma with the active pharmaceutical ingredients (API) of insulin at a “significantly reduced price” to enable cheaper, faster production of the life-saving medication that is used to treat diabetes, one of the fastest-growing health problems on the continent.